Developing new drugs for the treatment of ocular diseases can be a time-consuming and costly undertaking. The trip from laboratory to market can take anywhere between 10 to 20 years and will cost around US$1 billion.
Create a free Member account at NZ Optics to read this article and more.
Ocular melanoma, including choroidal, iris, and conjunctival types, is rare but serious. Early detection by optometrists and ophthalmologists through
Inherited retinal disorders (IRDs) comprise a heterogeneous group of diseases characterised by diverse modes of inheritance, including autosomal dominant, autosomal recessive, X-linked (recessive and dominant), mitochondrial inheritance and less common patterns, such as pseudodominance. This genetic
Eye on Ophthalmology takes a look into alternatives to frequent intravitreal injections.
As primary eyecare providers, we are likely to come across many lesions in the periocular area. It is important to have a simple and systematic approach to dealing with these during examination.
Introduction Uveitis encompasses a diverse group of inflammatory disorders affecting the uveal tract (iris, ciliary body, choroid) and adjacent structures such as the retina, vitreous, and optic nerve
Patients with glaucoma are at high risk for developing dry eye disease (DED)1, with 40–59% of patients with glaucoma being diagnosed with DED worldwide2. DED in glaucoma is multifactorial and can be